No Survival Benefit With Ipilimumab in Advanced Prostate Cancer

In a phase III trial, ipilimumab increased the overall survival of men with advanced castration-resistant prostate cancer when used with a single dose of radiotherapy by 1.2 months, but the results were not statistically significant.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

In this study, we investigated whether PSMA5 is associated with the tumorigenic progression and the interaction of PSMA5 with bortezomib in PCa. We knocked down PSMA5 with siRNA and studied the changes in cell viability and motility with Cell Counting Kit-8, quantitative PCR, fluorescence-activated cell sorting, scratch, and invasion assays. We also investigated the effect of PSMA5 in PCa cells treated with bortezomib and in those that are resistant to bortezomib. We found that silencing PSMA5 inhibited cell proliferation, induced apoptosis, restricted cell migration and invasion, and demonstrated a coordinated effect with...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Condition:   Prostatic Neoplasms Intervention:   Other: Observation Sponsors:   Swiss Group for Clinical Cancer Research;   ProteoMediX AG;   Cantonal Hospital of St. Gallen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 18 July 2019Source: European UrologyAuthor(s): Song Chen, Yu Xiao, Xinghuan Wang
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsMRI pathway had the most favourable outcome in significant and insignificant prostate cancer detection compared with systematic biopsy. The certainty in our findings was reduced by study limitations.Patient summaryWe reviewed recent advances in prostate biopsy by magnetic resonance imaging (MRI) guidance and targeting for prostate cancer detection in comparison with standard diagnosis by systematic biopsies. The findings of this Cochrane review suggest that MRI pathway is better than systematic biopsies in making a correct diagnosis of clinically important prostate cancer and reducing redundant biopsies and the ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
PROSTATE cancer occurs in the prostate gland which is located just below the bladder. It wraps around the tub that carries semen and urine through the penis. Having this sexual ailment could be an advanced warning sign. Do you have it?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Authors: Houédé N Abstract To date, systemic treatments, including hormone therapies or chemotherapy, are used at different stages of prostate cancer disease. Several types of complications can occur during systemic treatment in prostate cancer, depending on the therapeutic range. The most common with hormone therapy are fatigue, muscle loss, bone loss, high blood pressure and metabolic syndromes. For chemotherapy, the most significant risk is related to hematological toxicity, but peripheral neuropathies, mucositis, diarrhea and hypersensitivity reactions may also occur. The quality of the pre-treatm...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
In conclusion, multimodal regimens increase the risk of side effects compared to surgery or radiotherapy alone. Indications of these approaches muste be discussed with the patients after a careful evaluation of the benefit/risk ratio. PMID: 31307629 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
CONCLUSION: In absence of consensus or guidelines, management of prostate cancer should be an individualized, patient-based management taking into account primary tumor stage and grade, number and types of metastasis and patient characteristics. PMID: 31307628 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Authors: Erra B, Pradere B Abstract Nuclear medicine is a keystone specialty in the evaluation and management of prostate cancer. Its recent development, particularly through metabolic imaging and isotope therapy, has made it a major gamechanger in the management of metastatic prostate cancer. The aim of this article was to postpone its place within the various stages of the disease through a comprehensive review of national and international recommendations. PMID: 31307627 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Statistics | Yervoy